Recent

% | $
Quotes you view appear here for quick access.

Intel Corporation Message Board

uashg8 5 posts  |  Last Activity: May 22, 2015 6:11 PM Member since: Nov 19, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • U.S. House committee approves bill to speed new drugs to market
    Reuters article

    Sentiment: Strong Buy

  • Reply to

    Highest close

    by imfournursebee May 18, 2015 3:54 PM
    uashg8 uashg8 May 18, 2015 8:59 PM Flag

    Good point but don't forget cash value .We are sitting on cash pile and we haven't spend yet.

    Sentiment: Strong Buy

  • uashg8 uashg8 May 17, 2015 6:45 PM Flag

    I was myself wondering why bakers brother didn't knock on our door.Finally we got something which really excite me more about this investment.They are gems of bio and to have them on board speak volume.I hope they keep adding to their position.My thoughts are we have very bright future and we will see double digit very soon.Good luck to all my fellow investors.

    Sentiment: Buy

  • Reply to

    Institution ownership latest numbers

    by newlife3675 May 8, 2015 11:11 AM
    uashg8 uashg8 May 9, 2015 8:46 AM Flag

    Same here ...I have been trying to figure out what is happening with this company.I started to buy 3.30 $ my avg cost is not far off from where we are now.What makes me wonder high institution ownership and very high short interest.Now let's look at business they have more than 100 million $ in revenue.@250 million $ cash in bank .Burn rate is about 60 million $ at current rate.Now what is future first consider modest 25-40% growth yearly .CVOT trials going to cost about 50 million $ /year for first two years and then taper off.we may see less cost on this front if FDA accept EU test which currently going on .That is most likely going to happen as both agencies has MOU in place.Now we have about 250 million in debt and we are paying 8+ million $ on interest.I have read their agreement and it seems company has option to pay in terms of shares this may dilute little bit in 2017 or so.(I don't see it will happen like that but good to have in mind) . We also have South America partner and @300 million $ royalties rolling our way in future from ED drug .We got another indication in pipeline which will get materialize in 2017 .So in all this company is on solid ground until it starts it accent to northward.I am very confident considering all economics and science we will see 12-15$ mark in future.What are any other negative here ? Oh yes law suit which doesn't have any merits it is our legal system allow such nonsense but it we have to go through that anyways.( look in avanier pharmacy law suit they had generic compound with new formation and they won big time against Activist).Do your DD and don't listen to nonsense get posted on this board by some.We have winner here and game is played just buy as much as u can .

    Sentiment: Strong Buy

  • Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity






    Approval of naltrexone-bupropion by the FDA was based on the results of multiple clinical trials of approximately 4500 overweight and obese study participants. To date, 4 unique phase 3 studies of naltrexone-bupropion, all called CONTRAVE Obesity Research (COR), have evaluated the efficacy of the drug and have reported 1-year weight outcome data, using modified intent-to-treat (ITT) analysis as well as attrition



    Most participants were white women and only 2% were 65 years or older.



    Attrition in all studies was high, ranging from 42% to 50%, so that approximately only 53% of individuals who were enrolled in these trials completed 1 year while taking the study drug. Across studies, 24% of those taking naltrexone-bupropion withdrew due to adverse events (vs 12% taking placebo). Nausea was the most common adverse event leading to withdrawal.



    Common adverse effects of naltrexone-bupropion include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. Because naltrexone-bupropion can lead to elevations in blood pressure and pulse compared with placebo despite greater weight loss, this drug should not be used in patients with uncontrolled hypertension; blood pressure and pulse should be assessed prior to treatment and monitored regularly. Due to its bupropion component, the package insert includes a “black box” warning for potential increased risk of suicidality and also notes that serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation.



    For patients who respond to naltrexone-bupropion with clinically meaningful weight loss and improvements in obesity-related conditions, continued indefinite treatment may be warranted. If weight loss of at least 5% is not attained after 12 weeks at the full dose, the patient should be reevaluated and the medication discontinued.

    Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity






    Approval of naltrexone-bupropion by the FDA was based on the results of multiple clinical trials of approximately 4500 overweight and obese study participants. To date, 4 unique phase 3 studies of naltrexone-bupropion, all called CONTRAVE Obesity Research (COR), have evaluated the efficacy of the drug and have reported 1-year weight outcome data, using modified intent-to-treat (ITT) analysis as well as attrition



    Most participants were white women and only 2% were 65 years or older.



    Attrition in all studies was high, ranging from 42% to 50%, so that approximately only 53% of individuals who were enrolled in these trials completed 1 year while taking the study drug. Across studies, 24% of those taking naltrexone-bupropion withdrew due to adverse events (vs 12% taking placebo). Nausea was the most common adverse event leading to withdrawal.



    Common adverse effects of naltrexone-bupropion include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. Because naltrexone-bupropion can lead to elevations in blood pressure and pulse compared with placebo despite greater weight loss, this drug should not be used in patients with uncontrolled hypertension; blood pressure and pulse should be assessed prior to treatment and monitored regularly. Due to its bupropion component, the package insert includes a “black box” warning for potential increased risk of suicidality and also notes that serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation.



    For patients who respond to naltrexone-bupropion with clinically meaningful weight loss and improvements in obesity-related conditions, continued indefinite treatment may be warranted. If weight loss of at least 5% is not attained after 12 weeks at the full dose, the patient should be reevaluated and the medication discontinued.

    Sentiment: Buy

INTC
30.09-0.33(-1.07%)12:45 PMEDT